Dishman Carbogen Amcis last traded at ₹149.01 (2026-10-13). Over the past month the stock moved -11.6%, three months the stock moved -25.7%, year the stock moved -50.4%. Its closing range over 52 weeks is ₹142.69 – ₹291.80, with the latest close 48.9% below the high.
Closing prices up to 2026-10-13.
Dishman Carbogen Amcis Ltd is engaged in Contract Research and Manufacturing Services (CRAMS) and manufacture and supply of marketable molecules such as specialty chemicals, vitamins & chemicals and disinfectants with presence in Switzerland, UK, Europe, China and other countries.[1]
Business Segments & Revenue Contribution
In the latest quarter (Jun 2026), Dishman Carbogen Amcis reported sales of ₹678.00 crore (-4.2%) and net profit of ₹-58.00 crore (-352.2%), compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 678.00 | 60.00 | 9.00 | -58.00 | -3.69 |
| Mar 2026 | 851.00 | 163.00 | 19.00 | 22.00 | 1.39 |
| Dec 2025 | 720.00 | 113.00 | 16.00 | -13.00 | -0.83 |
| Sep 2025 | 653.00 | 149.00 | 23.00 | 65.00 | 4.16 |
| Jun 2025 | 708.00 | 141.00 | 20.00 | 23.00 | 1.49 |
| Mar 2025 | 716.00 | 153.00 | 21.00 | 43.00 | 2.75 |
| Dec 2024 | 682.00 | 140.00 | 21.00 | 5.00 | 0.30 |
| Sep 2024 | 789.00 | 147.00 | 19.00 | 33.00 | 2.11 |
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +34.4% | +4.8% | +9.3% | +35.1% | -17.2% | +5.6% | +18.9% | -4.2% |
| Operating profit growth | +141.0% | +241.5% | +142.9% | +386.2% | +1.4% | -19.3% | +6.5% | -57.4% |
| Net profit growth | – | – | – | – | +97.0% | -360.0% | -48.8% | -352.2% |
| EPS growth | – | – | – | – | +97.2% | -376.7% | -49.5% | -347.7% |
| OPM % | 19.0% | 21.0% | 21.0% | 20.0% | 23.0% | 16.0% | 19.0% | 9.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
In the latest year (Mar 2026), Dishman Carbogen Amcis reported sales of ₹2,932.00 crore (+8.1%) and net profit of ₹97.00 crore (+3133.3%), compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 2,932 | 566.00 | 19.00 | 97.00 | 6.22 |
| Mar 2025 | 2,712 | 469.00 | 17.00 | 3.00 | 0.21 |
| Mar 2024 | 2,616 | 286.00 | 11.00 | -153.00 | -9.79 |
| Mar 2023 | 2,413 | 332.00 | 14.00 | -30.00 | -1.90 |
| Mar 2022 | 2,141 | 331.00 | 15.00 | 18.00 | 1.15 |
| Mar 2021 | 1,912 | 274.00 | 14.00 | -165.00 | -10.53 |
| Mar 2020 | 2,044 | 503.00 | 25.00 | 159.00 | 10.10 |
| Mar 2019 | 2,059 | 552.00 | 27.00 | 210.00 | 13.03 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +21.5% | -0.7% | -6.5% | +12.0% | +12.7% | +8.4% | +3.7% | +8.1% |
| Operating profit growth | +24.0% | -8.9% | -45.5% | +20.8% | +0.3% | -13.9% | +64.0% | +20.7% |
| Net profit growth | +35.5% | -24.3% | -203.8% | – | -266.7% | – | – | +3133.3% |
| EPS growth | +36.0% | -22.5% | -204.3% | – | -265.2% | – | – | +2861.9% |
| OPM % | 27.0% | 25.0% | 14.0% | 15.0% | 14.0% | 11.0% | 17.0% | 19.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
No AI analysis generated yet for Dishman Carbogen Amcis.
Get Free AI Stock Analysis FREE →Dishman Carbogen Amcis shareholders approve all five AGM resolutions - scanx.trade
Dishman Carbogen Amcis shareholders approve all five AGM resolutions - scanx.trade
Dishman Carbogen Amcis’ arm clears USFDA inspection at Switzerland site with zero observations
Dishman Carbogen Amcis’ arm clears USFDA inspection at Switzerland site with zero observations
Dishman Carbogen Amcis consolidated net profit declines 49.55% in the March 2026 quarter - Business Standard
Dishman Carbogen Amcis shares were last quoted at ₹149.01 (-0.4% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
Dishman Carbogen Amcis has a price-to-earnings (P/E) ratio of 162.72 and a price-to-book (P/B) ratio of 0.40. The industry P/E is 53.33.
The 52-week high of Dishman Carbogen Amcis is ₹306.75 and the 52-week low is ₹129.00.
The market capitalisation of Dishman Carbogen Amcis is about ₹2,627.68 crore.
In the latest quarter (Jun 2026), Dishman Carbogen Amcis reported sales of ₹678.00 crore (-4.2%) and net profit of ₹-58.00 crore (-352.2%), compared with the same quarter last year.
This page is for information and is not investment advice. As per the data shown here, Dishman Carbogen Amcis has a 3-year ROE of 0.00%, 3-year profit growth of 140.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
Promoters hold about 59.32% of Dishman Carbogen Amcis.
Dishman Carbogen Amcis belongs to the Pharmaceuticals & Drugs sector.